The estimated Net Worth of Jason Gardner is at least $3.65 Million dollars as of 16 September 2021. Mr. Gardner owns over 14,340 units of Magenta Therapeutics Inc stock worth over $200,810 and over the last 6 years he sold MGTA stock worth over $1,794,131. In addition, he makes $1,651,000 as President, Chief Executive Officer, Co-Founder und Director at Magenta Therapeutics Inc.
Jason has made over 8 trades of the Magenta Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 14,340 units of MGTA stock worth $96,508 on 16 September 2021.
The largest trade he's ever made was selling 76,711 units of Magenta Therapeutics Inc stock on 20 December 2019 worth over $1,162,939. On average, Jason trades about 7,041 units every 66 days since 2018. As of 16 September 2021 he still owns at least 286,872 units of Magenta Therapeutics Inc stock.
You can see the complete history of Mr. Gardner stock trades at the bottom of the page.
Jason Gardner is a President, Chief Executive Officer, Co-Founder, Director of the Company. Dr. Gardner has more than 20 years of experience in stem cell science, drug development and industry leadership roles. He joined Atlas Venture in November 2015 as an Entrepreneur-in-Residence to create Magenta with Third Rock Ventures. He previously worked at GlaxoSmithKline plc. from 2005, most recently as Vice President and Head of the R&D Satellite in Boston. He created and led the Regenerative Medicine Unit, established partnerships with The Harvard Stem Cell Institute, and The Telethon Institute for Gene Therapy, from which the first stem cell gene therapy (Strimvelis) was approved. Prior to that, Dr. Gardner was the Head of the Center of Excellence for External Drug Discovery and was a member of the clinical project team that led the late stage development and NDA approval for Tykerb for breast cancer. Dr. Gardner held scientific leadership roles at Progenics Pharmaceuticals, Inc. and Chiron Corporation working on drug discovery and development. Dr. Gardner completed a postdoctoral fellowship in stem cell biology with Professor David Scadden at Harvard Medical School
As the President, Chief Executive Officer, Co-Founder und Director of Magenta Therapeutics Inc, the total compensation of Jason Gardner at Magenta Therapeutics Inc is $1,651,000. There are 1 executives at Magenta Therapeutics Inc getting paid more, with Christina Isacson having the highest compensation of $2,277,560.
Jason Gardner is 49, he's been the President, Chief Executive Officer, Co-Founder und Director of Magenta Therapeutics Inc since 2016. There are 12 older and 8 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.
Jason's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third... und Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.
Magenta Therapeutics Inc executives and other stock owners filed with the SEC include: